References

1. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin. 2018;44(6):1195-1203. doi:10.1093/schbul/sby058

2. GBD 2017 Disease and Injury Incidence and Prevalence, Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet. 392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7

3. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2(4):531-536. doi:10.2147/nedt.2006.2.4.531

4. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;(213):11-37. doi:10.1007/978-3-642-25758-2{\_}2

5. Kalache SM, Mulsant BH, Davies SJC, et al. The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. Schizophrenia Bulletin. 2014;41(2):374-381. doi:10.1093/schbul/sbu114

6. Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SOW, Christensen T Østergaard, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatrica Scandinavica. 2015;131(3):185-196. doi:10.1111/acps.12374

7. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. American Journal of Psychiatry. 2007;164(12):1791-1802. doi:10.1176/appi.ajp.2007.07060906

8. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. American Journal of Psychiatry. 2011;168(5):472-485. doi:10.1176/appi.ajp.2010.10060855

9. Revell ER, Neill JC, Harte M, Khan Z, Drake RJ. A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophrenia Research. 2015;168(1):213-222. doi:https://doi.org/10.1016/j.schres.2015.08.017

10. Kambeitz-Ilankovic L, Betz LT, Dominke C, et al. Multi-outcome meta-analysis (moma) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neuroscience and Biobehavioral Reviews. 2019;107:828-845. doi:https://doi.org/10.1016/j.neubiorev.2019.09.031

11. Kim EJ, Bahk Y-C, Oh H, Lee W-H, Lee J-S, Choi K-H. Current status of cognitive remediation for psychiatric disorders: A review. Frontiers in Psychiatry. 2018;9:461. doi:10.3389/fpsyt.2018.00461

12. Seccomandi B, Tsapekos D, Newbery K, Wykes T, Cella M. A systematic review of moderators of cognitive remediation response for people with schizophrenia. Schizophrenia Research: Cognition. 2020;19:100160. doi:https://doi.org/10.1016/j.scog.2019.100160

13. Fiszdon JM, Kurtz MM, Parente L, Choi J. What variables predict cognitive remediation associated improvement in individuals with psychosis? Schizophrenia Research: Cognition. 2020;19:100148. doi:https://doi.org/10.1016/j.scog.2019.100148

14. Barlati S, Deste G, Galluzzo A, et al. Factors associated with response and resistance to cognitive remediation in schizophrenia: A critical review. Frontiers in Pharmacology. 2019;9:1542. doi:10.3389/fphar.2018.01542

15. Hingorani AD, Windt DA van der, Riley RD, et al. Prognosis research strategy (progress) 4: Stratified medicine research. BMJ. 2013;346. doi:10.1136/bmj.e5793

16. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 51(6):1173-1182. doi:10.1037//0022-3514.51.6.1173

17. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and Moderators of Treatment Effects in Randomized Clinical Trials. Archives of General Psychiatry. 2002;59(10):877-883. doi:10.1001/archpsyc.59.10.877

18. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. Trials. 11:85. doi:10.1186/1745-6215-11-85

19. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340. doi:10.1136/bmj.c117

20. Hua H, Burke DL, Crowther MJ, Ensor J, Tudur Smith C, Riley RD. One-stage individual participant data meta-analysis models: Estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information. Statistics in Medicine. 2017;36(5):772-789. doi:10.1002/sim.7171

21. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine. 2008;27(11):1870-1893. doi:10.1002/sim.3165

22. Belias M, Rovers MM, Reitsma JB, Debray TPA, IntHout J. Statistical approaches to identify subgroups in meta-analysis of individual participant data: A simulation study. BMC Med Res Methodol. 19(1):183. doi:10.1186/s12874-019-0817-6